Home/Corbus Pharmaceuticals/Yuval Cohen, Ph.D.
YC

Yuval Cohen, Ph.D.

Chief Executive Officer and Director

Corbus Pharmaceuticals

Corbus Pharmaceuticals Pipeline

DrugIndicationPhase
CRB-701Nectin-4 expressing solid tumors (e.g., HNSCC, Cervical Cancer, mUC)Phase 1
CRB-701 (CSPC)Cervical CancerPhase 3
CRB-913Obesity and related conditionsPhase 1